Contents8 sections
Melanotan I and Melanotan 2 are synthetic peptides that stimulate melanin production in the skin, producing a tan without prolonged UV exposure. Both peptides are analogs of alpha-melanocyte stimulating hormone (a-MSH), the natural hormone that regulates skin pigmentation, but they differ significantly in receptor selectivity, half-life, and side effect profiles.
Melanotan I (Afamelanotide) is the more selective version, primarily targeting the MC-1R receptor responsible for melanogenesis. It has received medical approval in some regions for treating erythropoietic protoporphyria, a condition where sunlight causes severe skin reactions. Melanotan 2, a shorter 7-amino-acid peptide, is non-selective — it activates multiple melanocortin receptors, producing tanning effects alongside increased libido, appetite suppression, and other systemic effects.
Neither peptide is FDA-approved for cosmetic tanning. Both remain research chemicals in most jurisdictions, and understanding their mechanisms, dosing, and risks is essential for anyone considering their use.
Key Takeaways
- Melanotan I (13 amino acids) selectively targets MC-1R for tanning; Melanotan 2 (7 amino acids) is non-selective and affects multiple body systems.
- Both are synthetic analogs of alpha-MSH, the hormone that controls melanin production.
- Melanotan I has medical approval for erythropoietic protoporphyria under the brand name Scenesse.
- Melanotan 2 produces tanning plus sexual function enhancement, appetite suppression, and energy regulation.
- Neither peptide is FDA-approved for cosmetic use. Both carry dose-dependent side effects.
What Are Melanotan I and II?
Melanotan I (Afamelanotide)
Melanotan I is a 13-amino-acid synthetic peptide that mimics the body’s natural a-MSH hormone. It primarily activates the MC-1R (melanocortin-1 receptor), the receptor directly responsible for melanogenesis — the process by which melanocytes produce melanin pigment in the skin and hair.
Because Melanotan I is relatively selective for MC-1R, its effects are largely confined to skin pigmentation. Research has demonstrated that a-MSH analogs stimulate melanin synthesis in human melanocytes through cyclic AMP-dependent pathways, confirming the mechanism through which these peptides produce their effects.
Melanotan I has a longer half-life than Melanotan 2, which provides more stable blood levels and a more gradual tanning response. It is sold under the brand name Scenesse (Afamelanotide) and has been approved in the European Union for patients with erythropoietic protoporphyria who cannot tolerate sunlight.
Melanotan 2
Melanotan 2 is a shorter, 7-amino-acid cyclic peptide with non-selective activity across multiple melanocortin receptor subtypes. While it also activates MC-1R for tanning, it simultaneously targets MC-3R (appetite regulation), MC-4R (sexual function and energy homeostasis), and MC-5R (exocrine gland function).
This broad receptor activity explains why Melanotan 2 produces effects beyond skin darkening. The MC-4R activation is responsible for the peptide’s well-documented effects on erectile function and sexual arousal, while MC-3R activity influences appetite and fat metabolism. Melanotan 2 can cross the blood-brain barrier, which amplifies its central nervous system effects but also increases the potential for systemic side effects.
Melanotan I vs Melanotan II
| Factor | Melanotan I (Afamelanotide) | Melanotan 2 |
|---|---|---|
| Amino acid length | 13 | 7 |
| Receptor selectivity | Primarily MC-1R | Non-selective (MC-1R, MC-3R, MC-4R, MC-5R) |
| Half-life | Longer (more stable levels) | Shorter (requires more frequent dosing) |
| Primary effect | Skin tanning | Skin tanning + systemic effects |
| Sexual function effects | None | Significant (libido increase, erectile function) |
| Appetite effects | Minimal | Appetite suppression |
| Medical approval | EU-approved for EPP (Scenesse) | Not approved for any indication |
| Side effect severity | Generally mild | Higher risk of serious effects |
| Crosses blood-brain barrier | Limited | Yes |
The core difference between Melanotan I and Melanotan 2 comes down to selectivity. Melanotan I acts almost exclusively on the tanning pathway, making it the safer option for individuals who want skin darkening without systemic effects. Melanotan 2 offers additional benefits (sexual function, body composition effects) but at the cost of broader receptor activation and a higher side effect burden.
Benefits of Melanotan Peptides
Skin Tanning Without Prolonged UV Exposure
Both Melanotan I and Melanotan 2 stimulate melanocytes to produce melanin independent of UV radiation, though some sun exposure accelerates and deepens the tanning response. Clinical trials with Melanotan I showed that 75% of subjects achieved measurable skin darkening compared to placebo controls.
The practical advantage of these compounds is reduced UV exposure time. Users typically achieve a deep, natural-looking tan with minimal sunlight, which reduces the cumulative UV damage associated with traditional sunbathing or tanning beds. Melanotan I has even demonstrated photoprotective effects by increasing melanin density before sun exposure occurs.
Phototoxicity Prevention (Melanotan I)
The medical application of Melanotan I centers on erythropoietic protoporphyria (EPP), a condition where protoporphyrin accumulation in red blood cells causes severe pain and skin damage upon sunlight exposure. Afamelanotide implants increase melanin density enough to provide meaningful photoprotection, allowing EPP patients to tolerate sunlight for longer periods.
Sexual Function Enhancement (Melanotan 2)
Melanotan 2’s activation of MC-4R in the central nervous system produces a measurable increase in libido and erectile function. In clinical trials, 8 out of 10 men with erectile dysfunction experienced improvement after Melanotan 2 administration. This mechanism of action led to the development of PT-141 (Bremelanotide), a derivative of Melanotan 2 that is FDA-approved specifically for treating hypoactive sexual desire disorder.
Appetite Regulation and Body Composition (Melanotan 2)
Through MC-3R and MC-4R activation, Melanotan 2 suppresses appetite and may promote fat oxidation. These effects mimic aspects of leptin signaling and have generated research interest in Melanotan 2 as a potential treatment for obesity, though this application remains investigational.
Melanotan Dosage and Administration
Preparation
Both Melanotan peptides are supplied as lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water before injection. Typical reconstitution uses 1-2 mL of bacteriostatic water per vial. The reconstituted solution must be refrigerated and is generally stable for 4-6 weeks.
Dosage Guidelines
| Peptide | Starting Dose | Maintenance Dose | Administration |
|---|---|---|---|
| Melanotan I | 0.5 mg/day | 0.5-1 mg/day | Subcutaneous injection |
| Melanotan 2 | 0.1 mg/day | 0.25-0.5 mg/day | Subcutaneous injection |
Melanotan 2 is dosed lower than Melanotan I due to its higher potency and broader receptor activity. Starting at the lowest effective dose and titrating upward over several days allows the user to assess tolerance and minimize Melanotan side effects, particularly the nausea common in the first few administrations.
Administration
Both peptides are administered via subcutaneous injection, typically in the abdominal area. Nasal spray formulations exist but have lower bioavailability and less predictable absorption compared to injection. The injection process follows standard peptide reconstitution and subcutaneous administration protocols.
Tanning Timeline
Initial skin darkening typically appears within 1-2 weeks of daily use. Full tanning results usually develop over 3-4 weeks of consistent dosing. Once the desired tan is achieved, the dose can be reduced to a maintenance schedule of 2-3 injections per week to sustain the melanin response.
Some UV exposure (15-20 minutes of sunlight or a brief tanning bed session) during the loading phase accelerates and deepens the tanning response, though it is not strictly required for melanin production to begin.
Melanotan Side Effects
Melanotan I Side Effects
Melanotan I is generally well-tolerated, with most side effects being mild and transient:
| Side Effect | Frequency | Notes |
|---|---|---|
| Nausea | Common (early doses) | Usually resolves after first few injections |
| Appetite reduction | Common | Related to MC-3R activity |
| Facial flushing | Occasional | Temporary vasodilation |
| Headache | Occasional | Typically mild |
| Fatigue | Uncommon | Generally transient |
| Injection site reactions | Uncommon | Redness, mild soreness |
Melanotan 2 Side Effects
Melanotan 2 carries a more significant side effect profile due to its non-selective receptor activity:
| Side Effect | Frequency | Severity |
|---|---|---|
| Nausea | Very common | Moderate (especially initial doses) |
| Facial flushing | Common | Mild to moderate |
| Spontaneous erections/priapism | Common in males | Potentially serious if prolonged |
| Appetite suppression | Common | Can be significant |
| Mole/freckle darkening | Common | Cosmetic concern; may complicate skin cancer screening |
| Headache | Occasional | Mild to moderate |
| Fatigue/drowsiness | Occasional | Dose-dependent |
| Yawning | Occasional | CNS effect |
| Hyperpigmentation/melasma | Uncommon | Can persist after discontinuation |
| Rhabdomyolysis | Rare | Serious — skeletal muscle breakdown |
| Renal infarction | Rare | Life-threatening |
| Systemic toxicity | Rare | Related to overdose |
The most concerning Melanotan side effects with Melanotan 2 are the darkening of existing moles and freckles, which can obscure changes that indicate melanoma development, and the rare but serious cases of rhabdomyolysis and renal infarction reported in case studies. Bodybuilders and competitive athletes who use these compounds should schedule regular dermatological screenings to monitor mole changes.
The Bottom Line
Melanotan I and Melanotan 2 represent two approaches to synthetic tanning with distinctly different risk-benefit profiles.
- Melanotan I offers selective MC-1R activation for skin darkening with a favorable safety profile, and its medical approval for erythropoietic protoporphyria confirms its photoprotective efficacy.
- Melanotan 2 provides broader effects including sexual function enhancement and appetite suppression, but its non-selective receptor activity introduces a wider range of potential Melanotan side effects.
